Clinical trials in Catania – page 17

420 clinical trials in Catania, Italy across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in ItalyStudi-Clinici.it

Catania at a glance

420

clinical trials

Research sites2

Quick filters

420 trials in Catania

Open in trial search

Thyroid cancer+1

Not yet recruiting

Study of levothyroxine sodium plus liothyronine sodium vs levothyroxine sodium to control TSH in advanced thyroid cancer patients on tyrosine kinase inhibitors

Registered drugNo placebo

Study of levothyroxine sodium plus liothyronine sodium vs levothyroxine sodium to control TSH in advanced thyroid cancer patients on tyrosine kinase inhibitors

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Levothyroxine Sodium

Contact Research Centre

Plasma cell myeloma refractory

Not yet recruiting

Study of teclistamab plus autologous lymphocyte infusion in patients with relapsed or refractory multiple myeloma

Registered drugNo placebo

Study of teclistamab plus autologous lymphocyte infusion in patients with relapsed or refractory multiple myeloma

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Teclistamab
Sponsor:Fondazione Gimema Franco Mandelli Onlus

Contact Research Centre

A study to evaluate the safety and effectiveness of subcutaneous blinatumomab in adults and adolescents with relapsed, refractory, or minimal residual disease positive B-cell precursor acute lymphoblastic leukemia.

Registered drugNo placebo

A study to evaluate the safety and effectiveness of subcutaneous blinatumomab in adults and adolescents with relapsed, refractory, or minimal residual disease positive B-cell precursor acute lymphoblastic leukemia.

Registered drugNo placebo

Italy

Participants:0–17 years · 18–64 years · 65+ years
Substances:Blinatumomab
Sponsor:Amgen Inc.

Contact Research Centre

Lung cancer metastatic

Not yet recruiting

Study of Drug Combination with Pembrolizumab Guided by Blood Biomarkers for Patients with Metastatic Non-Small Cell Lung Cancer

Registered drugNo placebo

Study of Drug Combination with Pembrolizumab Guided by Blood Biomarkers for Patients with Metastatic Non-Small Cell Lung Cancer

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:IRCCS Istituto Nazionale Tumori Fondazione Pascale

Contact Research Centre

Testing inotuzumab ozogamicin and blinatumomab with drug combination for children with relapsed precursor B-cell acute lymphoblastic leukemia

Not yet recruiting

Registered drugNo placebo

Testing inotuzumab ozogamicin and blinatumomab with drug combination for children with relapsed precursor B-cell acute lymphoblastic leukemia

Registered drugNo placebo

Italy

Participants:0–17 years · 18–64 years
Substances:Blinatumomab
Sponsor:Charite Universitaetsmedizin Berlin KöR

Contact Research Centre

Acute lymphocytic leukaemia+2

Not yet recruiting

A Study of Blinatumomab in Children with Relapsed or Treatment-Resistant B Cell Acute Lymphoblastic Leukemia with Remaining Disease Traces

InvestigationalNo placebo

A Study of Blinatumomab in Children with Relapsed or Treatment-Resistant B Cell Acute Lymphoblastic Leukemia with Remaining Disease Traces

InvestigationalNo placebo

Italy

Participants:0–17 years
Substances:Blinatumomab
Sponsor:Amgen Inc.

Contact Research Centre

Non-small cell lung cancer

Not yet recruiting

Study of zipalertinib plus chemotherapy versus placebo plus chemotherapy in patients with stage IB-IIIA non-small cell lung cancer with uncommon EGFR mutations after surgery

Registered drug

Study of zipalertinib plus chemotherapy versus placebo plus chemotherapy in patients with stage IB-IIIA non-small cell lung cancer with uncommon EGFR mutations after surgery

Registered drug

Italy

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:Taiho Oncology Inc.

Contact Research Centre

Colorectal cancer

Not yet recruiting

Study of 5-Fluorouracil, Panitumumab, and Sotorasib for Patients with Advanced KRAS G12C Mutated Colorectal Cancer Not Eligible for Standard Chemotherapy

Registered drugNo placebo

Study of 5-Fluorouracil, Panitumumab, and Sotorasib for Patients with Advanced KRAS G12C Mutated Colorectal Cancer Not Eligible for Standard Chemotherapy

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Fluorouracil
Sponsor:Fondation Franc.Cancerologie Digestive

Contact Research Centre

Relapsing-remitting multiple sclerosis

Not yet recruiting

Study Comparing ABP 692 and Ocrelizumab for Patients with Relapsing-Remitting Multiple Sclerosis

Registered drugNo placebo

Study Comparing ABP 692 and Ocrelizumab for Patients with Relapsing-Remitting Multiple Sclerosis

Registered drugNo placebo

Italy

Participants:18–64 years
Substances:Ocrelizumab
Sponsor:Amgen Inc.

Contact Research Centre

Non-small cell lung cancer

Not yet recruiting

Study on the Best Treatment Sequence for Advanced Non-Small Cell Lung Cancer with EGFR Mutations Using Dacomitinib and Osimertinib

Registered drugNo placebo

Study on the Best Treatment Sequence for Advanced Non-Small Cell Lung Cancer with EGFR Mutations Using Dacomitinib and Osimertinib

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Dacomitinib
Sponsor:Fondazione Ricerca Traslazionale

Contact Research Centre

Genitourinary tract neoplasm

Not yet recruiting

Study on Niraparib for Patients with Advanced Urothelial Cancer After Initial Platinum Chemotherapy

Registered drugNo placebo

Study on Niraparib for Patients with Advanced Urothelial Cancer After Initial Platinum Chemotherapy

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Niraparib Tosilate Monohydrate
Sponsor:Universita' Degli Studi Di Torino

Contact Research Centre

Acute myeloid leukaemia

Not yet recruiting

Study on the Safety and Effectiveness of Fludarabine and Treosulfan for Stem Cell Transplant in Acute Myeloid Leukemia Patients Aged 40 to 65

Registered drugNo placebo

Study on the Safety and Effectiveness of Fludarabine and Treosulfan for Stem Cell Transplant in Acute Myeloid Leukemia Patients Aged 40 to 65

Registered drugNo placebo

Italy

Participants:18–64 years
Substances:Ciclosporin
Sponsor:Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia

Contact Research Centre

Other cities in Italy

The busiest research cities in the country

All 233 cities in Italy

Clinical research in Catania

What the registry says about research in the country

01 Oncology Studies

Innovative clinical trials focusing on metastatic colorectal cancer, multiple myeloma, and gastric cancer treatments. Research includes evaluation of targeted therapies and novel drug combinations.

Colorectal Cancer Treatments
Blood Cancer Therapies
Gastric Cancer Interventions

Studies aim to improve treatment outcomes through targeted therapies and immunotherapy approaches.

02 Respiratory Medicine

Research initiatives examining treatments for non-small cell lung cancer, asthma, and chronic rhinosinusitis. Focus on innovative therapeutic approaches and disease management.

Lung Cancer Treatments
Asthma Control Studies
Nasal Polyps Management

Trials evaluate new medications and combination therapies for respiratory conditions.

03 Dermatology Research

Clinical investigations into atopic dermatitis, psoriasis, and hidradenitis suppurativa. Studies focus on novel therapeutic approaches for chronic skin conditions.

Inflammatory Skin Conditions
Autoimmune Skin Disorders
Chronic Skin Disease Management

Evaluation of new biological treatments and targeted therapies for skin disorders.

Back to Italy All countries